24/7 Market News Snapshot 09 July, 2025 – Kazia Therapeutics Limited American Depositary Shares (NASDAQ:KZIA)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NASDAQ:KZIA) are discussed in this article.
Kazia Therapeutics Limited is currently experiencing a remarkable surge in investor interest, as evidenced by the pre-market price of its American Depositary Shares (KZIA) climbing to $11.55, an impressive increase of 69.23% from the previous closing price of $6.83. This robust activity is further highlighted by a significant trading volume of 4.98 million shares, indicating strong market confidence and positioning the company for potential transformative advancements in the biotech sector.

This enthusiasm is being amplified by the promising preliminary results from Kazia’s Phase 1b clinical trial that investigates a combination therapy involving Paxalisib, pembrolizumab (Keytruda®), and conventional chemotherapy. The trial’s first participant, a 61-year-old woman with metastatic triple-negative breast cancer, demonstrated substantial improvement after just 21 days, with over a 50% reduction in circulating tumor cells (CTCs) and a marked decrease in CTC clusters, which are associated with heightened metastatic potential.

These early outcomes align with previous preclinical studies showcasing Paxalisib’s effectiveness in disrupting not only individual CTCs but also clusters. Such findings enhance the drug’s profile as a potential synergistic agent in conjunction with immunotherapy. Furthermore, the reduction of the mesenchymal phenotype observed among the residual CTCs indicates a decline in aggressive cancer characteristics, underscoring the therapy’s potential in transforming treatment approaches.

Dr. John Friend, CEO of Kazia Therapeutics, emphasized the significance of these results, expressing optimism regarding the potential for the combination therapy to address systemic disease progression. The trial’s ongoing enrollment aims to further examine the correlation between CTC dynamics and patient outcomes, positioning Kazia at the forefront of pioneering innovative cancer treatments as the Phase 1b study progresses into further analysis of the immune microenvironment and CTC kinetics.

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.